中
繁
EN
Search form
Search this site
For Patients
Investors
Careers
Contact
Home
About Us
Our Story
Leadership
Board of Directors
Jacobio people stories
Platform & Pipeline
Platform
Pipeline
Publications
Partnership
News
Company News
Media Report
69
press releases in total
Year
-Year
2024
2023
2022
2021
2020
2019
2018
2022
Dec 16, 2022
Jacobio’s KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE
[More]
Dec 2, 2022
Jacobio’s Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022
[More]
Oct 29, 2022
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 in China
[More]
Oct 13, 2022
Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab
[More]
Sep 16, 2022
Jacobio Completes First Patient Dosage of JAB-21822’s Phase II Pivotal Study in China
[More]
Sep 6, 2022
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-21822’s Phase II Pivotal Study in China
[More]
Sep 2, 2022
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China
[More]
Sep 1, 2022
Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China
[More]
Aug 23, 2022
Jacobio Announces 2022 Interim Results
[More]
May 27, 2022
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting
[More]
Mar 28, 2022
Jacobio Receives IND Approval for CD73 mAb JAB-BX102 from China CDE
[More]
Mar 23, 2022
Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%
[More]
Feb 24, 2022
Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China
[More]
Jan 17, 2022
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA
[More]
2021
Dec 6, 2021
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China
[More]
Oct 15, 2021
Jacobio Receives IND Approval for CD73 mAb JAB-BX102 from FDA
[More]
Sep 1, 2021
Jacobio Pharmaceuticals Announces 2021 Interim Results
[More]
Aug 31, 2021
Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy
[More]
Aug 3, 2021
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumour
[More]
Jun 18, 2021
Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment
[More]
Pages
«
‹
1
2
3
4
›
»
京公网安备 11030102011242号